<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0609</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2026-04-20</periodOfReport>

    <issuer>
        <issuerCik>0002091349</issuerCik>
        <issuerName>First Tracks Biotherapeutics, Inc.</issuerName>
        <issuerTradingSymbol>TRAX</issuerTradingSymbol>
        <issuerForeignTradingSymbol></issuerForeignTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001370053</rptOwnerCik>
            <rptOwnerName>ANAPTYSBIO, INC</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag>
            <rptOwnerStreet1>10770 WATERIDGE CIRCLE, SUITE 210</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>SAN DIEGO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>9212</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>true</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock, par value $0.001 per share</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <transactionDate>
                <value>2026-04-20</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>J</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F2"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>100</value>
                    <footnoteId id="F3"/>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">On April 1, 2026, AnaptysBio, Inc., a Delaware corporation (&quot;AnaptysBio&quot;), reported that it owned 100 shares of common stock, par value $0.001 per share, of First Tracks Biotherapeutics, Inc. (&quot;First Tracks&quot;), which at the time constituted all of the issued and outstanding shares of common stock of First Tracks.</footnote>
        <footnote id="F2">The record date for the distribution by AnaptysBio of all shares of common stock of First Tracks to the holders of AnaptysBio common stock was April 20, 2026 (the &quot;Spin-Off&quot;). The Spin-Off occurred before the market opened on April 20, 2026.</footnote>
        <footnote id="F3">Represents the outstanding shares of common stock of First Tracks as of April 20, 2026, which were distributed in the Spin-Off as defined in footnote 2 on April 20, 2026.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Dan Faga, Chief Executive Officer and President of AnaptysBio, Inc.</signatureName>
        <signatureDate>2026-04-22</signatureDate>
    </ownerSignature>
</ownershipDocument>
